LETTER TO EDITOR

A consistent arrhythmogenic trait in Brugada syndrome cellular phenotype

To the Editor:

Brugada syndrome (BrS) is an inherited arrhythmic disease predisposing to sudden cardiac death (SCD), characterized by a typical electrocardiogram pattern that includes a J point elevation with a coved type ST segment.\(^1\) BrS is a complex genetic disease in which \(\sim 20\%\) of patients carry rare variants in \(SCN5A\) gene, whereas the others remain genetically unresolved.\(^2\) Despite this genetic complexity, we hypothesize that a common cellular phenotypic trait is at the root of this specific BrS ECG pattern. In this study, we identified a phenotype that is common to human-induced pluripotent stem cell-derived ventricular cardiomyocytes (hiPSC-CMs) generated from six Brugada patients with different genetic backgrounds. Our results unmasked a cellular arrhythmogenic phenotype combining gene expression and electrical abnormalities, including an increase in late sodium current.

Six patients affected by type I BrS (BrS1-6; Figure S1; Tables S1 and S2) with a familial history of SCD or syncope were selected, among whom two carry \(SCN5A\) variants (marked with a + symbol). An additional individual, not affected by BrS (non-BrS), carrying the same \(SCN5A\) variant as BrS2+ was also recruited, as well as four control (Ctrl) subjects. Somatic cells from all studied subjects were reprogrammed into hiPSC lines and differentiated into cardiomyocytes (Figure 1).

Transcriptional expression profiling identified 133 differentially expressed genes in BrS hiPSC-CMs (Figure 2A). Gene set enrichment analyses showed that transcripts of transmembrane transporters and channels were significantly overrepresented (Figure 2B), including genes encoding sodium, calcium, and potassium channels (Figure 2C). High-throughput real-time RT-PCR\(^3\) on 96 genes related to cardiac electrical function (Table S3) identified 13 differentially expressed genes in BrS, in comparison to Ctrl and non-BrS hiPSC-CMs (Figure 2D). Importantly, the expression of \(SCN5A\), the main BrS culprit gene identified to date,\(^4\) remained unchanged, excluding \(SCN5A\) expression levels as a hallmark for BrS hiPSC-CM phenotype. Conversely, calcium and sodium transporters, playing important roles in membrane depolarization, were differentially expressed. Comparative analysis of hiPSC-CM electrophysiological functions investigated whether these modifications were a consistent trait of BrS phenotype at the cellular level.

Whereas decrease in sodium current is considered as the most frequently associated electrical alteration in BrS pathophysiology,\(^5,6\) protein expression of \(Na_v1.5\), encoded by \(SCN5A\), was decreased in only two BrS, and the non-BrS lines (Figure 2E). Concordantly, reduction in \(I_{Na}\) density was detected in these same lines (Figure 2F–H). This confirmed previous results, for BrS\(^+\),\(^7\) and regarding BrS1+, which carries an \(SCN5A\) rare variant, the reduction was confirmed using conventional transfection in COS-7 cells of this variant (Figure S2). Furthermore, the steady-state activation and inactivation gating properties were not modified in BrS hiPSC-CMs (Figure S3A; Table S4). Therefore, \(I_{Na}\) reduction is not a common trait of BrS hiPSC-CMs and appears to be solely associated with the presence of variants affecting \(SCN5A\) expression or function.

Similarly, reduction in \(I_{Ca,L}\) channel protein expression and current density were not a common trait of BrS hiPSC-CMs (Figure 2I–L, Figure S3B; Table S4).

Global cellular electrophysiological phenotype was then evaluated with action potential (AP) recordings, but no AP basal parameters specifically segregated BrS hiPSC-CMs, and spontaneous beating frequencies did not differ between all cell lines (Figure S4). Noteworthy, ventricular-like AP analysis revealed an arrhythmic phenotype present mostly in BrS hiPSC-CMs, irrespective of their genetic background (Figure 3A). Early afterdepolarizations (EADs) were observed in 39–70% of all six BrS ventricular-like hiPSC-CMs versus only in 4% and 4.7% of Ctrl and non-BrS hiPSC-CMs, respectively (Figure 3B, Figure S5). Thereby, the high EAD occurrence in ventricular-like hiPSC-CMs was associated with the presence of a BrS

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2021 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics
FIGURE 1  Pluripotency and SCN5A variant validation in hiPSCs, and characterization of derived cardiomyocytes. (A) Transcript expression of pluripotency markers: NANOG and OCT3/4 in newly described hiPSCs as compared to fibroblasts (Fibro). (B) Representative immunostainings of TRA1-60 (red) and OCT4 (green) in hiPSCs. (C) Percentage of hiPSCs expressing SSEA4 and TRA1-60 evaluated by flow cytometry. (D) Genomic sequence chromatograms validating (right) the 5164A>G SCN5A variant carried by BrS1+ and (left) the SCN5A 1983-1993 duplication carried by BrS2+ and non-BrS, in the corresponding hiPSCs. (E) Principal component analysis (PCA) of 39 hiPSC samples and their corresponding differentiated hiPSC-CMs, based on their expression pattern of 27106 analyzed transcripts (3′SRP data). All clones of each hiPSC line are highlighted. (F) Correlation matrix of hiPSCs and hiPSC-CMs expression profiles. Yellow and orange indicate high and low correlation, respectively. Samples were clustered using an ascending hierarchical method with Pearson as metric and ward D2 linkage. (G) Heatmap showing expression levels of 9661 differentially expressed genes between hiPSCs and hiPSC-CMs (same samples as in A). Genes were clustered using a hierarchical ascending method with an uncentered correlation metric and complete linkage. Yellow and blue indicate high and low levels, respectively. (H) Illustrative immunostainings of Troponin I (green) in hiPSC-CMs. Nuclei were stained with DAPI (blue). (I) Percentages of nodal-like, atrial-like, and ventricular-like cells classified based on the analysis of spontaneous action potential recordings.
**FIGURE 2** Differential gene expression profiles and variations in $I_{Na}$ and $I_{Ca,L}$ in BrS hiPSC-CMs as compared to controls. (A) Heatmap showing hierarchical clustering of expression profiles of 133 differentially expressed genes obtained by 3′SRP in control (Ctrl) and BrS hiPSC-CMs at day 28 of differentiation. A total of 27% were upregulated, whereas 73% genes were downregulated in BrS hiPSC-CMs. Yellow and blue represent high and low expression levels, respectively. All clones of each hiPSC line are highlighted. (B) Transmembrane transporter activity. (C) MindMap describing the transmembrane transporter activity alterations. (D) Expression levels of differentially expressed genes identified using high-throughput TaqMan (TLDA) in BrS hiPSC-CMs ($n = 14$), compared to control hiPSC-CMs ($n = 12$), and in non-BrS hiPSC-CMs ($n = 4$) versus BrS hiPSC-CMs. $p$-values: * $p < .05$, ** $p < .01$, and *** $p < .001$ versus Ctrl or BrS, respectively (t-test). (E) Representative immunoblots for NaV1.5 and transferrin receptor (TFRC) in hiPSC-CMs (left panel). Ratios of NaV1.5 expression levels (right panel, Tukey plot, $n = 8$). * $p < .05$ versus control (Mann–Whitney test). NaV1.5 decreases in hiPSC-CMs from three subjects, BrS2+ and non-BrS (both carrying a stop codon in SCN5A), as well as BrS5−, harboring RRAD variant was observed. (F) Representative superimposed $I_{Na}$ densities (inset: voltage-clamp protocol). Reduction was detected in BrS2+, BrS5−, and non-BrS, as well as in BrS1+ hiPSC-CMs carrying the N1722D-SCN5A rare variant. (G) Peak $I_{Na}$ densities measured in control (Ctrl), BrS, and the non-affected carrier of SCN5A mutation (non-BrS) hiPSC-CMs determined at −20 mV (Tukey plot). *** $p < .001$ versus control (Mann–Whitney test). (H) Mean peak $I_{Ca,L}$ densities (pA/pF) versus membrane potential ($V_m$) recorded in hiPSC-CMs. **** $p < .0001$ versus control for BrS1+, BrS2+, BrS5+, and non-BrS, respectively (two-way ANOVA with Bonferroni post hoc test). (I) Representative immunoblots for CAV1.2, the main pore-forming subunit of the cardiac L-type calcium channel, and transferrin receptor (TFRC) in hiPSC-CMs (left panel). Ratios of CAV1.2 expression levels (right panel, Tukey plot, $n = 8$). A decrease in CAV1.2 expression was solely observed in BrS5− hiPSC-CMs, carrying an RRAD-variant. * $p < .05$ versus control (Mann–Whitney test). (J) Representative superimposed $I_{Ca,L}$ densities (inset: voltage protocol). (K) Peak $I_{Ca,L}$ densities measured in control (Ctrl), BrS, and the non-affected carrier of SCN5A mutation (non-BrS) hiPSC-CMs determined at 0 mV (Tukey plot). A decrease in $I_{Ca,L}$ was observed in BrS2+, BrS4− and, consistently with a previous description, in BrS5−. * $p < .05$ and ** $p < .01$ versus control (Mann–Whitney test). (L) Mean peak $I_{Ca,L}$ densities (pA/pF) versus membrane potential ($V_m$) recorded in hiPSC-CMs. *, #, and $\$ \ p < .05$, **, ##, and $$ $ \ p < .01$, and $$$, ###, and $$$ $ \ p < .001$ versus control for BrS1+, BrS4−, and BrS5−, respectively (two-way ANOVA with Bonferroni post hoc test).
Increased early after depolarization (EAD) occurrence in all BrS ventricular-like hiPSC-CM lines, linked to an increase in late sodium current. (A) Representative AP recordings, showing EADs in BrS lines only. Representative ventricular-like AP when paced at 700 ms cycle length and when artificial I_{K1} was injected (dynamic current clamp). APs are defined as ventricular-like when (APD_{30} − APD_{40})/(APD_{70} − APD_{80}) > 1.45. (B) Percentage of ventricular-like hiPSC-CMs presenting at least 1 EAD, irrespective of the current clamp conditions. *p < .05, **p < .01, and ***p < .001 versus control (Fisher’s exact test). (C) Representative I_{Na,L} recordings from hiPSC-CMs, before (black) and after (grey) TTX application (inset: voltage protocol). (D) I_{Na,L} (TTX-sensitive current) densities at −10 mV. *p < .05 and ***p < .001 versus Ctrl (Mann–Whitney test), and **p < .01 and ***p < .001 versus non-BrS (Mann–Whitney test). (E) Percentage of cells presenting I_{Na,L} density greater than the 97th percentile value of I_{Na,L} in the Ctrl hiPSC-CMs. **p < .01 and ***p < .001 versus control (Fisher’s exact test). Indeed, an increase in I_{Na,L} density was defined by values higher than 97th percentile of the Ctrl hiPSC-CMs. (F) Representative example of I_{Na,L} current recorded in BrS hiPSC-CMs before (black) and after (red) application with GS-458967 (300 nM), a specific I_{Na,L} inhibitor (inset: voltage protocol). (G) Representative AP recordings from control and BrS hiPSC-CMs obtained before and after GS-458967 application. (H) Percentage of cells with EADs before and after GS-458967 application. (I) Poincaré plots showing APD_{90} of each AP (n + 1) versus APD_{90} of its preceding one, before and after GS-458967 application.

phenotype in the investigated cell lines, but not with the presence of a variant in SCN5A.

The occurrence of EADs may be linked to an abnormally high density of depolarizing late sodium current (I_{Na,L}) during APs repolarizing phase. Accordingly, BrS hiPSC-CMs presented with a higher density of I_{Na,L} as compared to Ctrl and non-BrS hiPSC-CMs (Figure 3C,D). Moreover, an increase in I_{Na,L} density was observed only in 6% and 12% of Ctrl and non-BrS hiPSC-CMs respectively, in accordance with their low EAD occurrence, whereas increased I_{Na,L} density was present in 50–85% of all BrS ventricular-like hiPSC-CMs, reminiscent of the high EAD occurrence (Figure 3B,E). We then superfused ventricular-like BrS hiPSC-CMs during AP recording with GS-458967 (6-(4-(trifluoromethoxy)phenyl)-3-(trifluoromethyl)-1H-[1,2,4]triazolo[4,3-a]pyridine, which selectively blocks late sodium current), causing full inhibition of I_{Na,L} (Figure 3F), and found abolishment of EADs (Figure 3G,H) and reduced APD_{90} dispersion (Figure 3I). Altogether, these data strongly suggested that the abnormal increase of I_{Na,L} in BrS hiPSC-CMs is responsible for EADs.

Further strengthening the role of I_{Na,L} in the electrical cellular phenotype of BrS, when each ECG parameter was tested for its correlation with either I_{Na,L} or I_{Na} measured densities, only I_{Na,L} density correlated significantly with one sole parameter, that is, the J point elevation (Table S5).
To challenge the pathophysiological relevance of the ion current alterations identified in non-BrS and BrS2+ hiPSC-CMs, we applied them to a mathematical human electrogram model that allows visualizing transmural-like electrogram with a QRS-like complex, a ST-like segment, and a T-like wave (Figure 4A). First, in accordance with BrS2+ patient’s ECG, applying the alterations observed in peak $I_{Na}$, $I_{Ca,L}$, and in $I_{Na,L}$ in BrS2+ hiPSC-CMs was sufficient to induce prolongation of the QRS-like complex, ST-like segment elevation and widening, and T-like wave inversion (Figure 4B). Then, sequential correction of each altered current in BrS2+ hiPSC-CMs was made (BrS2+ corrected). Correction of $I_{Na}$ density led to QRS-like complex normalization; correction of $I_{Ca,L}$ density shortened duration of the ST-like segment elevation and normalized the T-like wave orientation; and correction of $I_{Na,L}$ density led to reduction of ST-like segment amplitude toward normalization (Figure 4C, left to right). Overall, these results strongly
suggest that depolarizing current alterations can impact a multicellular electrogram model, mimicking BrS ECG phenotype.

In conclusion, in the present study, a particular cellular electrophysiological phenotype common to six out of six BrS hiPSC-CM lines with various genetic backgrounds has been unveiled. We showed that high EAD occurrence associates with an abnormal increase of $I_{Na,L}$ in all investigated BrS cell lines, and correlates with the corresponding patients’ J point elevation on ECG. We focused on the ventricular cell type, at a single-cell level. Implementation of emerging phenotypic technologies, such as single-cell transcriptomics and cardiac tissue engineering, will allow investigation of the potential involvement of other cardiac cell types in the disease phenotype and the role of specific cell-to-cell interactions. Altogether, the obtained results open perspectives to better understand the ventricular arrhythmia occurrence in BrS and to identify a dedicated therapeutic approach to prevent the risk of SCD.

**ACKNOWLEDGMENTS**
The authors thank Dr. Connie Bezzina and Dr. Isabella Mengarelli for the gift of hiPSCs from BrS-patient, Dr. Pierre Lindenbaum and Dr. Stephanie Bonnaud for the Haloplex targeted capture and NGS experiments, and Adeline Goudal for her support in the variant annotation. Genomic and bioinformatics analysis, flow cytometry, and iPSCs derivation were performed with the support of GenoBiRD (Biogenouest), CytoCell, and iP core facility of Nantes University, respectively. Finally, the authors are grateful to the patients and families who agreed to participate in our research. This work was supported by grants from the Fondation pour la Recherche Médicale (DEQ20140329545), National Research Agency ANR-14-CE10-0001-01 and La Fédération Française de Cardiologie. Dr. Nathalie Gaborit was laureate of grants from Fondation Lefoulon-Delalande and Marie Curie Actions, International Incoming Fellowship FP7-PEOPLE-2012-IIF (PIIF-GA-2012-331436) and H2020-MSCA-IF-2014 (RISTRAD-661617); Eiffel Program of Excellence; Fondation Genavie; Association of Scientific Orientation and Specialization; Lebanese University; Data-Santé (Région Pays de la Loire)

**CONFLICT OF INTEREST**
The authors declare that there is no conflict of interest.

**DATA AVAILABILITY STATEMENT**
In accordance with the “DFG Guidelines on the Handling of Research Data,” the authors declare that all data supporting the findings of this study are available within the article and its supporting information files or from the corresponding author upon reasonable request. The dataset will be archived for at least 10 years after publication.

**FUNDING INFORMATION**
Fondation pour la Recherche Médicale, Grant Number: DEQ20140329545; National Research Agency: Grant Number: ANR-14-CE10-0001-01 and HEART-iPS Grant Number: ANR-15-CE14-0019-01; La Fédération Française de Cardiologie; Fondation Lefoulon-Delalande; Marie Curie Actions: International Incoming Fellowship, Grant Number: FP7-PEOPLE-2012-IIF (PIIF-GA-2012-331436) and H2020-MSCA-IF-2014 (RISTRAD-661617); Eiffel Program of Excellence; Fondation Genavie; Association of Scientific Orientation and Specialization; Lebanese University; Data-Santé (Région Pays de la Loire)

Zeina R. Al Sayed1,
Mariam Jouni1,
Jean-Baptiste Gourraud1,2,
Nadjet Belbachir1,
Julien Barc1,
Aurore Girardeau1,
Virginie Forest1,
Aude Derevier3,
Anne Gaignerie3,
Caroline Chariau3,
Bastien Cimarosti1,
Robin Canac1,
Pierre Olchesqui1,
Eric Charpentier1,
Jean-Jacques Schott1,2,
Richard Redon1,2,
Isabelle Bar1,
Vincent Probst1,2,
Flavien Charpentier1,2,
Gildas Loussouarn1,
Kazem Zibara4,
Guillaume Lamirault1,2,
Patricia Lemarchand1,2,
Nathalie Gaborit1

1 l’institut d’ thorax, Inserm, CNRS, UNIV Nantes, Nantes, France
2 l’institut d’ thorax, CHU Nantes, Nantes, France
3 Nantes Université, CHU Nantes, Inserm, CNRS, SFR Santé, Nantes, France
4 Laboratory of Stem Cells, PRASE, Biology Department, Faculty of Sciences, Lebanese University, Beirut, Lebanon
Correspondence
Nathalie Gaborit and Patricia Lemarchand, l’institut du thorax, Inserm UMR 1087, CNRS UMR 6291, IRS-UN, 8 quai Moncousu, 44007 Nantes cedex 1, France.
Email: nathalie.gaborit@univ-nantes.fr; patricia.lemarchand@univ-nantes.fr

ORCID
Zeina R. Al Sayed https://orcid.org/0000-0002-0661-2003
Jean-Baptiste Gourraud https://orcid.org/0000-0002-6961-2131
Julien Barc https://orcid.org/0000-0003-4106-5946
Virginie Forest https://orcid.org/0000-0003-2774-5232
Pierre Olchesqui https://orcid.org/0000-0002-4336-2218
Eric Charpentier https://orcid.org/0000-0002-8571-7603
Jean-Jacques Schott https://orcid.org/0000-0002-9578-9475
Richard Redon https://orcid.org/0000-0001-7751-2280
Isabelle Baró https://orcid.org/0000-0003-4850-4171
Vincent Probst https://orcid.org/0000-0002-5492-8619
Flavien Charpentier https://orcid.org/0000-0002-5057-0998
Gildas Loussouarn https://orcid.org/0000-0001-8007-5931
Kazem Zibara https://orcid.org/0000-0002-9887-072X
Guillaume Lamirault https://orcid.org/0000-0001-6490-1279
Patricia Lemarchand https://orcid.org/0000-0002-5330-2008
Nathalie Gaborit https://orcid.org/0000-0002-5231-6555

REFERENCES
1. Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Heart Rhythm. 2013;10:1932-1963.
2. Gourraud J-B, Barc J, Thollet A, et al. The Brugada syndrome: a rare arrhythmia disorder with complex inheritance. Front Cardiovasc Med. 2016;3:9.
3. Al Sayed ZR, Canac R, Cimarosti B. Human model of IRX5 mutations reveals key role for this transcription factor in ventricular conduction. Cardiovasc Res. 2020;8:259.
4. Kapplinger JD, Tester DJ, Alders M, et al. An international compendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing. Heart Rhythm. 2010;7:33-46.
5. Yan GX, Antzelevitch C. Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST-segment elevation. Circulation. 1999;100:1660-1666.
6. Meregalli PG, Wilde AA, Tan HL. Pathophysiological mechanisms of Brugada syndrome: depolarization disorder, repolarization disorder, or more? Cardiovasc Res. 2005;67:367-378.
7. Belbachir N, Portero V, Al Sayed ZR, et al. RRAD mutation causes electrical and cytoskeletal defects in cardiomyocytes derived from a familial case of Brugada syndrome. Eur Heart J. 2019;40:3081-3094.
8. Shryock JC, Song Y, Rajamani S, et al. The arrhythmogenic consequences of increasing late INa in the cardiomyocyte. Cardiovasc Res. 2013;99:600-611.
9. Potet F, Egecioglu DE, Burridge PW. GS-967 and eleclazine block sodium channels in human induced pluripotent stem cell-derived cardiomyocytes. Mol Pharmacol. 2020;98:540-547.
10. Gima K, Rudy Y. Ionic current basis of electrocardiographic waveforms: a model study. Circ Res. 2002;90:889-896.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section at the end of the article.